Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.
Found 31 results
Filters: Author is Wu, Juan [Clear All Filters]
“Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.”, Lancet Haematol, 2022.
, “A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.”, Transplant Cell Ther, 2022.
, “Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
, “Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.”, Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
, “Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.”, Biol Blood Marrow Transplant, vol. 26, no. 3, pp. 606-611, 2020.
, “Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.”, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
, “A confirmation of chronic graft--host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation.”, Haematologica, vol. 104, no. 7, pp. e314-e317, 2019.
, “Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601.”, Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.
, “Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with ”, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
, “Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.”, Blood Adv, vol. 2, no. 15, pp. 1882-1888, 2018.
, “A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801.”, Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
, “Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial.”, Bone Marrow Transplant, vol. 53, no. 8, pp. 1038-1043, 2018.
, “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.”, J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
, “Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.”, Blood, vol. 129, no. 2, pp. 162-170, 2017.
, “Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.”, JAMA Oncol, vol. 2, no. 12, pp. 1583-1589, 2016.
, “Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.”, Biol Blood Marrow Transplant, vol. 22, no. 2, pp. 359-370, 2016.
, “Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).”, Cancer, vol. 122, no. 1, pp. 91-8, 2016.
, “Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ”, Biol Blood Marrow Transplant, vol. 22, no. 8, pp. 1440-1448, 2016.
, “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.”, Blood, vol. 128, no. 21, pp. 2561-2567, 2016.
, “Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.”, Lancet Haematol, vol. 2, no. 9, pp. e367-75, 2015.
, “Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1530-6, 2014.
, “Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.”, J Clin Oncol, vol. 32, no. 22, pp. 2365-72, 2014.
, “Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1485-92, 2014.
, “Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne”, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
, “Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.”, Blood, vol. 124, no. 8, pp. 1372-7, 2014.
,